This study examined factors that help predict whether patients with early rheumatoid arthritis will achieve clinical remission. The analysis included 388 patients on methotrexate alone and 743 patients taking abatacept plus methotrexate. Data came from randomized trials and an observational clinic cohort.
Researchers looked at disease activity at presentation and early response to treatment as potential predictors. They also tested whether genetic markers, imaging results, or serology added value to these predictions. The results showed that only the initial disease activity and early response consistently predicted remission at six and twelve months.
No safety concerns were reported in this analysis. However, the study notes that determining which patients will achieve remission remains challenging. Readers should understand that adding more biological or imaging data does not currently make prediction models more accurate. This highlights the need for continued research into better prognostic tools.